CN Patent

CN110709071A — 用于施用某些vmat2抑制剂的方法

Assigned to Nuroclery Biosciences Co Ltd · Expires 2020-01-17 · 6y expired

What this patent protects

提供了向有需要的患者施用选自缬苯那嗪和(+)‑α‑3‑异丁基‑9,10‑二甲氧基‑1,3,4,6,7,11b‑六氢‑2H‑吡啶并[2,1‑a]异喹啉‑2‑醇或其药物可接受的盐和/或同位素变体的囊泡单胺转运体2(VMAT2)抑制剂的方法，其中所述患者正在用细胞色素P450 3A4(CYP3A4)强诱导剂进行治疗。

USPTO Abstract

提供了向有需要的患者施用选自缬苯那嗪和(+)‑α‑3‑异丁基‑9,10‑二甲氧基‑1,3,4,6,7,11b‑六氢‑2H‑吡啶并[2,1‑a]异喹啉‑2‑醇或其药物可接受的盐和/或同位素变体的囊泡单胺转运体2(VMAT2)抑制剂的方法，其中所述患者正在用细胞色素P450 3A4(CYP3A4)强诱导剂进行治疗。

Drugs covered by this patent

valbenazine-tosylate (VALBENAZINE TOSYLATE)

Patent Metadata

Patent number: CN110709071A
Jurisdiction: CN
Classification: —
Expires: 2020-01-17
Drug substance claim: No
Drug product claim: No
Assignee: Nuroclery Biosciences Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.